Efficacy and Safety of Itepekimab for Moderate-to-Severe Asthma | NEJM
Visual Abstract from the New England Journal of Medicine — Efficacy and Safety of Itepekimab for Moderate-to-Severe Asthma
Related Articles
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis | NEJM
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclero…
Antiretroviral Therapy for Children with HIV in Africa | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Antiretroviral Therapy for Children with HIV in Africa
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa | NEJM
Children living with human immunodeficiency virus (HIV) have limited options for second-line antiretroviral therapy (ART). In this open-label trial with a 2-by-4 factorial design, we…
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…
Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.